DK1218372T3 - Nye heterocykliske forbindelser, der er anvendelige som reversible inhibitorer af cysteinproteaser - Google Patents
Nye heterocykliske forbindelser, der er anvendelige som reversible inhibitorer af cysteinproteaserInfo
- Publication number
- DK1218372T3 DK1218372T3 DK00959506T DK00959506T DK1218372T3 DK 1218372 T3 DK1218372 T3 DK 1218372T3 DK 00959506 T DK00959506 T DK 00959506T DK 00959506 T DK00959506 T DK 00959506T DK 1218372 T3 DK1218372 T3 DK 1218372T3
- Authority
- DK
- Denmark
- Prior art keywords
- heterocyclic compounds
- compounds useful
- cysteine proteases
- novel heterocyclic
- reversible inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15373899P | 1999-09-13 | 1999-09-13 | |
US22290000P | 2000-08-03 | 2000-08-03 | |
PCT/US2000/023584 WO2001019816A1 (fr) | 1999-09-13 | 2000-08-28 | Composes spiroheterocycliques utiles comme inhibiteurs reversibles de cysteine protease |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1218372T3 true DK1218372T3 (da) | 2003-10-20 |
Family
ID=26850810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00959506T DK1218372T3 (da) | 1999-09-13 | 2000-08-28 | Nye heterocykliske forbindelser, der er anvendelige som reversible inhibitorer af cysteinproteaser |
Country Status (30)
Country | Link |
---|---|
EP (1) | EP1218372B1 (fr) |
JP (1) | JP2003529546A (fr) |
KR (1) | KR20030024651A (fr) |
CN (1) | CN100410250C (fr) |
AR (1) | AR032136A1 (fr) |
AT (1) | ATE244235T1 (fr) |
AU (1) | AU782246B2 (fr) |
BG (1) | BG106483A (fr) |
BR (1) | BR0013966A (fr) |
CA (1) | CA2385130C (fr) |
CZ (1) | CZ2002844A3 (fr) |
DE (1) | DE60003702T2 (fr) |
DK (1) | DK1218372T3 (fr) |
EE (1) | EE200200132A (fr) |
ES (1) | ES2199856T3 (fr) |
HK (1) | HK1048807A1 (fr) |
HR (1) | HRP20020221A2 (fr) |
HU (1) | HUP0302380A2 (fr) |
IL (2) | IL148184A0 (fr) |
MY (1) | MY122696A (fr) |
NO (1) | NO323354B1 (fr) |
NZ (1) | NZ518255A (fr) |
PL (1) | PL364045A1 (fr) |
PT (1) | PT1218372E (fr) |
RU (1) | RU2255937C2 (fr) |
SA (1) | SA00210456B1 (fr) |
SK (1) | SK286463B6 (fr) |
TW (1) | TWI230159B (fr) |
WO (1) | WO2001019816A1 (fr) |
YU (1) | YU17402A (fr) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0200503A3 (en) | 1999-03-15 | 2005-06-28 | Axys Pharmaceuticals Inc South | N-cyanomethyl amides as protease inhibitors and pharmaceutical compositions containing them |
US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
US7030116B2 (en) | 2000-12-22 | 2006-04-18 | Aventis Pharmaceuticals Inc. | Compounds and compositions as cathepsin inhibitors |
AR036375A1 (es) * | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
IL160819A0 (en) | 2001-09-14 | 2004-08-31 | Aventis Pharma Inc | Novel compounds and compositions as cathepsin inhibitors |
AU2002340031A1 (en) * | 2001-10-02 | 2003-04-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cysteine proteases |
WO2003037892A1 (fr) * | 2001-10-29 | 2003-05-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Composes convenant comme inhibiteurs reversibles de proteases de la cysteine |
CA2467391A1 (fr) | 2001-11-14 | 2003-05-22 | Aventis Pharmaceuticals Inc. | Nouveaux composes et compositions jouant le role d'inhibiteurs de cathepsine s |
EP1483241A4 (fr) | 2002-03-08 | 2006-12-13 | Bristol Myers Squibb Co | Derives cycliques servant de modulateurs de l'activite du recepteur de la chimiokine |
WO2004000838A1 (fr) * | 2002-06-24 | 2003-12-31 | Axys Pharmaceuticals, Inc. | Composes peptidiques en tant qu'inhibiteurs de la protease a cysteine |
GEP20115290B (en) | 2002-11-27 | 2011-09-26 | Incyte Corp | 3-aminopyrrolidine derivatives as modulators of chemokine receptors |
EP1569954A1 (fr) * | 2002-12-05 | 2005-09-07 | Axys Pharmaceuticals, Inc. | Derives de cyanomethyle en tant qu'inhibiteurs de la protease a cysteine |
US7384970B2 (en) | 2003-03-24 | 2008-06-10 | Irm Llc | Inhibitors of cathepsin S |
US7109243B2 (en) | 2003-03-24 | 2006-09-19 | Irm Llc | Inhibitors of cathepsin S |
WO2004108661A1 (fr) * | 2003-06-04 | 2004-12-16 | Axys Pharmaceuticals | Composes amidino servant d'inhibiteurs de proteases a cysteine |
US7173051B2 (en) | 2003-06-13 | 2007-02-06 | Irm, Llc | Inhibitors of cathepsin S |
US7256207B2 (en) | 2003-08-20 | 2007-08-14 | Irm Llc | Inhibitors of cathepsin S |
CA2521811A1 (fr) | 2003-09-18 | 2005-03-31 | Axys Pharmaceuticals, Inc. | Composes contenant un haloalkyle utilise comme inhibiteurs de cysteine protease |
US7297714B2 (en) * | 2003-10-21 | 2007-11-20 | Irm Llc | Inhibitors of cathepsin S |
JP5154944B2 (ja) | 2004-12-02 | 2013-02-27 | ビロベイ,インコーポレイティド | システインプロテアーゼインヒビターとしてのスルホンアミド含有化合物 |
WO2006102243A2 (fr) | 2005-03-21 | 2006-09-28 | Applera Corporation | Composes alpha-cetoamide utilises en tant qu'inhibiteurs de cysteine protease |
EP1866277B1 (fr) | 2005-03-22 | 2014-06-25 | Virobay, Inc. | Composes contenant du sulfonyle en tant qu'inhibiteurs de cysteine proteases |
AU2006259573A1 (en) * | 2005-06-14 | 2006-12-28 | Pharmacopeia, Inc. | Heterocyclic aspartyl protease inhibitors, preparation and use thereof |
US8067457B2 (en) | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
WO2007053499A2 (fr) | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Composés pouvant être employés en tant qu'antagonistes de ccr2 |
UY30090A1 (es) * | 2006-01-16 | 2007-08-31 | Syngenta Participations Ag | Insecticidas novedosos |
UA107583C2 (ru) | 2006-06-01 | 2015-01-26 | Санофі-Авентіс | Спироциклические нитрилы как ингибиторы протеазы |
US7893112B2 (en) | 2006-10-04 | 2011-02-22 | Virobay, Inc. | Di-fluoro containing compounds as cysteine protease inhibitors |
KR101555931B1 (ko) | 2006-10-04 | 2015-09-30 | 비로베이, 인코포레이티드 | 시스테인 프로테아제 억제제로서의 디플루오로 함유 화합물 |
DE102006057036A1 (de) * | 2006-12-04 | 2008-06-05 | Bayer Cropscience Ag | Biphenylsubstituierte spirocyclische Ketoenole |
WO2009087379A2 (fr) | 2008-01-09 | 2009-07-16 | Amura Therapeutics Limited | Composés |
EP2198879A1 (fr) | 2008-12-11 | 2010-06-23 | Institut Curie | Agent modulateur de CD74 pour la régulation de la migration de cellules dendritiques et dispositif pour l'étude de la capacité de motilité d'une cellule |
US8324417B2 (en) | 2009-08-19 | 2012-12-04 | Virobay, Inc. | Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof |
WO2012151319A1 (fr) | 2011-05-02 | 2012-11-08 | Virobay, Inc. | Inhibiteur de cathepsine pour le traitement du cancer des os et de la douleur provoquée par le cancer des os |
CN104744409A (zh) * | 2011-06-07 | 2015-07-01 | 株式会社吴羽 | 氧杂环丁烷化合物的制造方法、唑甲基环戊醇化合物的制造方法、以及中间体化合物 |
EP2537532A1 (fr) | 2011-06-22 | 2012-12-26 | J. Stefan Institute | Composés capables de se lier à une cathepsine, liés à un nanodispositif et leur utilisation thérapeutique et diagnostique |
GB2511685A (en) | 2011-11-18 | 2014-09-10 | Heptares Therapeutics Ltd | Muscarinic m1 receptor agonists |
GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
GB201617454D0 (en) * | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
US11124497B1 (en) | 2020-04-17 | 2021-09-21 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
KR20230040386A (ko) * | 2020-06-09 | 2023-03-22 | 파르데스 바이오사이언시스, 인크. | 시스테인 프로테아제의 억제제 및 이의 사용 방법 |
US11174231B1 (en) | 2020-06-09 | 2021-11-16 | Pardes Biosciences, Inc. | Inhibitors of cysteine proteases and methods of use thereof |
IL305789A (en) * | 2021-03-10 | 2023-11-01 | Vincere Biosciences Inc | USP30 inhibitors and uses thereof |
WO2023044171A1 (fr) * | 2021-09-20 | 2023-03-23 | Pardes Biosciences, Inc. | Inhibiteurs de cystéine protéases et leurs méthodes d'utilisation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5776718A (en) * | 1995-03-24 | 1998-07-07 | Arris Pharmaceutical Corporation | Reversible protease inhibitors |
CZ298197A3 (cs) * | 1995-03-24 | 1998-03-18 | Arris Pharmaceutical Corporation | Reverzibilní inhibitory proteas |
TW438591B (en) * | 1995-06-07 | 2001-06-07 | Arris Pharm Corp | Reversible cysteine protease inhibitors |
HUP0200503A3 (en) * | 1999-03-15 | 2005-06-28 | Axys Pharmaceuticals Inc South | N-cyanomethyl amides as protease inhibitors and pharmaceutical compositions containing them |
-
2000
- 2000-08-28 HU HU0302380A patent/HUP0302380A2/hu unknown
- 2000-08-28 WO PCT/US2000/023584 patent/WO2001019816A1/fr not_active Application Discontinuation
- 2000-08-28 EP EP00959506A patent/EP1218372B1/fr not_active Expired - Lifetime
- 2000-08-28 PT PT00959506T patent/PT1218372E/pt unknown
- 2000-08-28 NZ NZ518255A patent/NZ518255A/en unknown
- 2000-08-28 KR KR1020027003368A patent/KR20030024651A/ko not_active Application Discontinuation
- 2000-08-28 AT AT00959506T patent/ATE244235T1/de not_active IP Right Cessation
- 2000-08-28 BR BR0013966-1A patent/BR0013966A/pt not_active Expired - Fee Related
- 2000-08-28 AU AU70818/00A patent/AU782246B2/en not_active Ceased
- 2000-08-28 EE EEP200200132A patent/EE200200132A/xx unknown
- 2000-08-28 YU YU17402A patent/YU17402A/sh unknown
- 2000-08-28 CN CNB008146772A patent/CN100410250C/zh not_active Expired - Fee Related
- 2000-08-28 RU RU2002107433/04A patent/RU2255937C2/ru not_active IP Right Cessation
- 2000-08-28 PL PL00364045A patent/PL364045A1/xx unknown
- 2000-08-28 DE DE60003702T patent/DE60003702T2/de not_active Expired - Lifetime
- 2000-08-28 ES ES00959506T patent/ES2199856T3/es not_active Expired - Lifetime
- 2000-08-28 CZ CZ2002844A patent/CZ2002844A3/cs unknown
- 2000-08-28 SK SK490-2002A patent/SK286463B6/sk not_active IP Right Cessation
- 2000-08-28 CA CA002385130A patent/CA2385130C/fr not_active Expired - Fee Related
- 2000-08-28 DK DK00959506T patent/DK1218372T3/da active
- 2000-08-28 IL IL14818400A patent/IL148184A0/xx active IP Right Grant
- 2000-08-28 JP JP2001523393A patent/JP2003529546A/ja active Pending
- 2000-09-11 TW TW089118587A patent/TWI230159B/zh not_active IP Right Cessation
- 2000-09-11 MY MYPI20004216A patent/MY122696A/en unknown
- 2000-09-13 AR ARP000104795A patent/AR032136A1/es not_active Suspension/Interruption
- 2000-10-17 SA SA00210456A patent/SA00210456B1/ar unknown
-
2002
- 2002-02-14 IL IL148184A patent/IL148184A/en not_active IP Right Cessation
- 2002-03-05 BG BG106483A patent/BG106483A/bg active Pending
- 2002-03-12 HR HR20020221A patent/HRP20020221A2/hr not_active IP Right Cessation
- 2002-03-12 NO NO20021207A patent/NO323354B1/no unknown
-
2003
- 2003-02-06 HK HK03100843.6A patent/HK1048807A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1218372T3 (da) | Nye heterocykliske forbindelser, der er anvendelige som reversible inhibitorer af cysteinproteaser | |
NO20031065D0 (no) | Spiroheterocykliske nitriler nyttige som reversible inhibitorer av cysteinproteaser | |
CY2016042I1 (el) | Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων | |
NO20053340D0 (no) | Substituerte dihydropyrano-indol-3,4-dion-derivater som inhibitorer for plasmigogenaktivator-1 (CPAI-1). | |
DK1485354T3 (da) | Sulfonylamino-derivater som nye inhibitorer af histandeacetylase | |
DK1562902T3 (da) | 2-pyridonderivater som inhibitorer af neutrofilelastase | |
NO20043642L (no) | Heterocykiske tripeptider som hepatitt C inhibitorer | |
NO20022649L (no) | Heterocykliske dihydropyrimidiner som kaliumkanal inhibitorer | |
DK1485348T3 (da) | Carbonylamino-derivater som nye inhibitorer af histandeacetylase | |
NO20040933L (no) | Nye gamma-sekretaseinhibitorer. | |
NO20043793L (no) | Nikotinamidderivater anvendelige som PDE4 inhibitorer | |
DK1562589T3 (da) | Diaminotriazoler der er nyttige som inhibitorer af proteinkinaser | |
DK1060178T3 (da) | Heterocyklisk forbindelser som inhibitorer af rotamase enzymer | |
SE0502338L (sv) | Azaspiroalkanderivat som hämmare av metalloproteaser | |
NO20014483D0 (no) | Aminderivater som proteaseinhibitorer | |
NO20010322L (no) | Heterocykliske forbindelser som inhibitorer av rotamaseenzymer | |
NO20061317L (no) | Imidazopyridinderivater som induserbare NO-syntaseinhibatorer | |
DK1178986T3 (da) | Furanonderivater som inhibitorer af cathepsin S | |
DK1600441T3 (da) | Krystallinsk form af elrcanidipinhydrochlorid til anvendelse som et antihypertensivt middel | |
NO20061344L (no) | Imidazopyridinderivater som induserbare NO-syntaseoinhibitorer | |
DK0928291T3 (da) | 3-Mercaptoacetylamino-1,5-substituerede 2-oxo-azepanderivater, der er nyttige som inhibitorer af matrixmetalloproteinase | |
NO20023001D0 (no) | Substituerte piperazinderivater som MTP inhibitorer | |
DK1217002T3 (da) | 2-(4-pyridinyl)benzofuraner som metalloproteaseinhibitorer | |
DK1637141T3 (da) | Stabiliseret proteasesammensætning omfattende en serinprotease, morpholinderivater og reversible inhibitorer af serinproteasen | |
NO20032290D0 (no) | Nye forbindelser for anvendelse som HIV-protease-inhibitorer |